Biotechnology - Eylea

Filter

Current filters:

Eylea

Popular Filters

Positive two-year Ph III VISTA trial of Eylea in DME

Positive two-year Ph III VISTA trial of Eylea in DME

10-02-2014

US biotech firm Regeneron Pharmaceuticals and partner Germany’s Bayer have released positive results…

BayerBiotechnologyEyleaOphthalmicsRegeneronResearch

Regeneron and Bayer expand deal to develop new option for wet-AMD

Regeneron and Bayer expand deal to develop new option for wet-AMD

14-01-2014

US biotech firm Regeneron Pharmaceuticals said yesterday that it has expanded its accord with German…

BayerBiotechnologyEyleaLicensingOphthalmicsRegeneronResearch

Drug approvals for Bayer in USA and Japan

Drug approvals for Bayer in USA and Japan

23-11-2013

There were two pieces of good news for German Pharma and chemicals major Bayer on Friday (November 22),…

AmgenAsia-PacificBayerBiotechnologyEyleaNexavarNorth AmericaOncologyOnyx PharmaceuticalsOphthalmicsPharmaceuticalRegeneronRegulation

Regeneron 3rd-qtr beats expectations, as total revenues leap 40%

Regeneron 3rd-qtr beats expectations, as total revenues leap 40%

06-11-2013

US biotech firm Regeneron Pharmaceuticals has posted financial and operating results for the third quarter…

BayerBiotechnologyEyleaFinancialOphthalmicsRegeneron

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

Regeneron revenues leap on Eylea progress

06-08-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) saw its shares fall 4% to $260 in pre-market…

BayerBiotechnologyEyleaFinancialRegeneron

Eylea meets primary endpoint in Ph III DME study

06-08-2013

German pharma major Bayer (BAYN: DE) revealed this morning (August 6) that, in the Phase III VIVID-DME…

BayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronResearch

Positive Ph III results for Regeneron/Bayer's Eylea in mCNV

06-06-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) and partner Germany's Bayer (BAYN: DE) have…

BayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronResearch

Regeneron acquires rights to two ophthalmology programs from Sanofi

03-05-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) has expanded its ophthalmology portfolio by…

BiotechnologyEyleaFinancialLicensingOphthalmicsPharmaceuticalRegeneronSanofi

Regeneron posts strong growth for 2012, beating analysts' estimates

15-02-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) yesterday announced that total revenues were…

BiotechnologyEyleaFinancialOncologyOphthalmicsRegeneronZaltrap

Recent Eylea growth in USA appears to be coming from expanded uptake among prescribers

07-01-2013

After one year on the market, 86% of US retinal specialists have prescribed Regeneron's (Nasdaq: REGN)…

BayerBiotechnologyEyleaMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneron

Bayer files for Japanese approval of Eylea for macular edema following CRVO

07-01-2013

German drug major Bayer(BAYN: DE) says its subsidiary Bayer Yakuhin has applied to the Japanese Ministry…

afliberceptAsia-PacificBayerBiotechnologyEyleaOphthalmicsPharmaceuticalRegeneronRegulationSanten Pharmaceuticals

Novartis' Lucentis captures two-thirds of wet-AMD patient share in Europe

28-11-2012

Retinal specialists in the EU5 (France, Germany, Italy, Spain and the UK) treat 66% of intravitreal-pharmaceutically-treated…

AvastinBayerBiotechnologyEuropeEyleaLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalRoche

Regeneron ups Eylea forecast, posts 2011 results

14-02-2012

USA-based biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) saw its shares leap 12% to $114.10 in…

BayerBiotechnologyEyleaFinancialOphthalmicsRegeneronResearch

FDA approves Regeneron’s Eylea for wet age-related macular degeneration

21-11-2011

Following unanimous advisory panel support for the drug, the US Food and Drug Administration has approved…

BayerBiotechnologyEyleaNorth AmericaOphthalmicsPharmaceuticalRegeneronRegulation

US FDA delays decision on Regeneron’s wet AMD drug Eylea

18-08-2011

US biotech firm Regeneron Pharmaceuticals. (Nasdaq: REGN) says that it has received notification from…

BayerBiotechnologyEyleaNorth AmericaOphthalmicsRegeneronRegulation

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top